ClinicalTrials.gg
RecruitingNCT05938478PROTECTUpdated Nov 20, 2026

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

An observational study in Atopic Dermatitis and Eczema, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of California, San Diego · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
20th of 94
900 · median 155
Started
2022
with 44 others
Observational
94 of 639
26 open now
Primary completion
2034-11
later than 108 of 115 live
Registered
505th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 20th largest by planned enrollment of the 94 observational ones that give a count, is one of 45 that started in 2022, is one of 94 observational ones, reaches primary completion later than 108 of the 115 other live ones, and was the 505th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy.

The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the study.

Participants will be asked to:

  • Complete 1-3 phone interviews during pregnancy and 1-2 phone interviews after delivery
  • Release medical records for pregnancy and for their child
  • Complete an online survey about their baby's development at 4 months and 12 months of age
  • May be asked to have a study doctor examine their child

All information is collected remotely, and no visits to the study site are required.

Read the detailed description

This Organization of Teratology Information Specialists (OTIS) Pregnancy Registry, is a United States (US) based registry designed to monitor pregnancy and infant outcomes among women in the US and Canada. This study is a prospective, observational cohort study of pregnancy and infant outcomes in pregnant people with exposure to tralokinumab for atopic dermatitis compared to people who have atopic dermatitis who have not used tralokinumab during pregnancy.

Researchers will compare pregnancy outcomes of those who were exposed to tralokinumab during pregnancy to pregnancy outcomes in people who did not use tralokinumab anytime in pregnancy, or 16 weeks prior to pregnancy, but who may or may not have used another medication to treat their atopic dermatitis during pregnancy. Information about infant health will be collected through one year of age.

03

Conditions studied

  • Atopic Dermatitis
  • Eczema

Keywords

  • AD
  • Eczema
  • Atopic dermatitis
  • Tralokinumab
  • Adbry
  • Adtralza
  • Pregnancy
  • Infant
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes pregnant women who reside in the US or Canada.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility for the cohort study includes the following:

  1. Currently pregnant at the time of enrollment
  2. Reside in the US or Canada at the time of enrollment
  3. Verbal to participate OTIS Pregnancy Registry
  4. Current diagnosis of AD at the time of enrollment

Cohort 1: Tralokinumab-Exposed Cohort

  1. Diagnosed with AD
  2. Exposure to tralokinumab for any number of days, at any dose, and at any time during pregnancy or within 16 weeks prior to the date of conception
  3. Agree to the conditions and requirements of the study including the interview schedule, dysmorphology exam (for the first 80 pregnancies resulting in live born infants), developmental screening, and release of medical records

Cohort 2: AD Comparator I- Phototherapy or Systemic Treatment

  1. Diagnosed with AD
  2. Exposed to phototherapy and/or systemic therapy for the treatment of AD for any number of days, at any dose, and at any time within 5 half-lives prior to the date of conception or during pregnancy
  3. Agree to the conditions and requirements of the study including the interview schedule, dysmorphology exam (for the first 80 pregnancies resulting in live born infants), developmental screening, and release of medical records

Cohort 3: AD Comparator II - With or Without Treatment

  1. Diagnosed with AD
  2. May or may not have received treatment for AD, but have not been exposed to any dose of phototherapy or systemic therapy for the treatment of AD within 5 half-lives prior to the estimated date of conception or any time during pregnancy.
  3. Agree to the conditions and requirements of the study including the interview schedule, dysmorphology exam (for the first 80 pregnancies resulting in live born infants), developmental screening, and release of medical records

Exclusion criteria

Exclusion Criteria:

Pregnant women meeting any of the following criteria will not be included in the cohort study:

Cohort 1: Tralokinumab-Exposed Cohort

  1. Women who have enrolled in the tralokinumab cohort study with a previous pregnancy
  2. Exposure to any dose of methotrexate or mycophenolate mofetil within 5 half-lives prior to the estimated date of conception or anytime during pregnancy
  3. Retrospective enrollment after the outcome of pregnancy is known (i.e., the pregnancy has ended prior to enrollment)
  4. Results of a diagnostic test are positive for a major structural birth defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect

Cohort 2: AD Therapy Comparator I- Phototherapy or Systemic Treatment

  1. Pregnant women who have enrolled in the tralokinumab cohort study with a previous pregnancy
  2. Exposure to any dose of tralokinumab, methotrexate or mycophenolate mofetil within 5 half-lives prior to the estimated date of conception or anytime during pregnancy.
  3. Retrospective enrollment after the outcome of pregnancy is known (i.e., the pregnancy has ended prior to enrollment)
  4. Results of a diagnostic test are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect

Cohort 3: AD Therapy Comparator II - With or Without Treatment

  1. Pregnant women who have enrolled in the tralokinumab cohort study with a previous pregnancy
  2. Exposure to any dose of tralokinumab, methotrexate or mycophenolate mofetil within 5 half-lives prior to the estimated date of conception or anytime during pregnancy
  3. Exposure to any dose of phototherapy and/or systemic therapy for the treatment of AD within 5 half-lives prior to the estimated date of conception or during pregnancy
  4. Retrospective enrollment after the outcome of pregnancy is known (i.e., the pregnancy has ended prior to enrollment)
  5. Results of a diagnostic test are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect

Case-Series: Tralokinumab-Exposed Case Series

Pregnancies with tralokinumab exposure that do not meet the exposed cohort (Cohort 1) criteria will be excluded from the cohort, but will be included in the Exposure Series. Women who are eligible for enrollment in the Exposure Series include, but are not limited to the following: exposed to tralokinumab during pregnancy for an indication other than AD, women who enrolled with a previous pregnancy in the cohort, and retrospective reports of a tralokinumab-exposed pregnancy after the outcome of pregnancy is known. With , data will be collected from those enrolled in the Exposure Series from maternal interviews and medical record review using the same protocol as the cohort study to the extent possible.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Tralokinumab-Exposed Cohort

    Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception

    Drug: Tralokinumab

  • AD Cohort- Phototherapy or Systemic Treatment Exposed

    Pregnant women with AD who have not been exposed to tralokinumab, but who have been exposed to phototherapy or systemic therapy for the treatment of AD during pregnancy

  • AD Cohort - With or Without Treatment

    Pregnant women with AD who may or may not have received treatment for AD, but who have not been exposed to any dose of tralokinumab, phototherapy or systemic therapy during pregnancy

  • Tralokinumab-Exposed Case Series

    Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception, who don't meet the eligibility criteria for the tralokinumab-exposed cohort group

    Drug: Tralokinumab

Interventions

  • This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.

    Also known as: Adbry, Adtralza

06

What researchers measure

Primary outcomes

  1. Prevalence of Major Structural Birth Defects

    Major structural defects is defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects. All major structural defects will be adjudicated by the co-investigator on this study.

    Time frame: Up to 1-year of age

Secondary outcomes

  1. Number of pregnancies ending in Spontaneous Abortion/Miscarriage

    Spontaneous abortion/miscarriage is defined as non-deliberate fetal death that occurs prior to 20 weeks after the first day of the last menstrual period (LMP).

    Time frame: Up to 20 weeks post-LMP

  2. Number of pregnancies ending in Stillbirth

    Stillbirth is defined as non-deliberate fetal death anytime in gestation at or after 20 weeks after the first day of the last menstrual period (LMP).

    Time frame: From 20 weeks post-LMP to end of pregnancy

  3. Number of pregnancies ending in Elective Termination/Abortion

    Elective termination/abortion is defined as deliberate termination of pregnancy through medication or surgical procedures. Elective abortions are classified for medical or social reasons.

    Time frame: At the completion of pregnancy; before 40 weeks post-LMP

  4. Number of pregnancies ending in Premature Delivery

    Premature delivery is defined as live birth prior to 37 weeks gestation as counted from LMP (or calculated from first-trimester ultrasound-derived due date if LMP uncertain or more than 1 week discrepant).

    Time frame: Through 9 months of pregnancy

  5. A Pattern of Minor Structural Birth Defects

    A pattern of 3 or more minor structural defects occurring in at least two children in any of the cohorts and identified by a study examiner based on the study-related physical examination.

    Time frame: Through completion of the study; an average of 1 year

  6. Number of children who are Small for Gestational Age

    Small for gestational age is defined as birth size (weight, length or head circumference) less than the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants.

    Time frame: At birth

  7. Number of children who are Small for Age for Postnatal Growth

    Small for age for postnatal growth is defined as postnatal size (weight, length or head circumference) less than the 10th centile for sex and age using National Center for Health Statistics (NCHS) pediatric growth curves, and adjusted postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age.

    Time frame: Up to 1 year of age

  8. Number of children diagnosed with a Serious or Opportunistic Infections

    A diagnosis of tuberculosis, x-ray proven pneumonia, neonatal sepsis, meningitis, bacteremia, invasive fungal infection, pneumocystitis, septic arthritis, osteomyelitis, abscess (deep tissue), and infections requiring hospitalization identified in live born infants

    Time frame: Up to 1 year of age

  9. Screening for Neurodevelopmental Milestones

    Screening for neurodevelopment performed using the Ages and Stages Questionnaire (ASQ). An abnormal score is defined in the scoring guidelines. Abnormal scores of clinical concern are defined by test-based, standardized scoring criteria reported in the ASQ-3 User's Guide. These represent scores that are less than two standard deviations below the mean for each category. Borderline scores are scores that fall between 2.0 and 1.5 standard deviations below the mean. The ASQ-3 does not provide a borderline score range but they suggest that children be monitored when they have scores 1.0 - 2.0 standard deviations below the mean.

    Time frame: 4 months and 12 months of age

  10. Number of Perinatal, Neonatal, or Infant Deaths

    Stillbirth is defined as non-deliberate fetal death anytime in gestation at or after 20 weeks after the first day of the last menstrual period (LMP). Neonatal death is defined as death of live born infant within 28 days of delivery. Infant death is defined as death of a live born infant \>28 days old to 1 year of life.

    Time frame: From 20 weeks gestation to 12 months of age

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2034, 143 months after the start.

Of 98 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 143 months is above that.

Counting every sponsor, half of 172 studies reached it within 47 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jul 10, 2023
StartActual
Dec 8, 2022
Primary completionEst.
Nov 30, 2034
CompletionEst.
Sep 30, 2035
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of California San Diego (UCSD) · La Jolla, United StatesContact person changed (no phone or email listed)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of California San Diego (UCSD) · La Jolla, United StatesContact person changed (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05938478
Collaborators
LEO Pharma, The Organization of Teratology Information Specialists
Responsible party
Christina Chambers (Principal Investigator, Professor, Chief of the Division of Environmental Science and Health, University of California, San Diego) — Principal investigator
First posted
Jul 10, 2023
Start date
Dec 8, 2022
Primary completion
Nov 30, 2034 (estimated)
Completion
Sep 30, 2035 (estimated)
Last update
Nov 20, 2026

Study contacts

Diana Johnson, MS
Contact
mothertobaby@health.ucsd.edu
877-311-8972

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion